A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
NCT06603285 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2025-08-15
Summary
This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil in subjects with pulmonary arterial hypertension.
Conditions
Interventions
- DRUG
-
Treprostinil
sc/iv continuously
Sponsors & Collaborators
-
Excelsior
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-10-16
- Primary Completion
- 2029-05-31
- Completion
- 2029-12-31
More Related Trials
-
Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
NCT00643604 ·Status: TERMINATED ·Phase: PHASE4
-
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT03794583 ·Status: TERMINATED ·Phase: PHASE3
-
Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)
NCT02074449 ·Status: COMPLETED
-
Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD
NCT03012646 ·Status: WITHDRAWN ·Phase: PHASE2
-
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
NCT00458042 ·Status: TERMINATED ·Phase: PHASE4
-
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
NCT02603068 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
NCT00741819 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
NCT05147805 ·Status: COMPLETED ·Phase: PHASE2
-
Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension
NCT04309838 ·Status: UNKNOWN
-
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
NCT03950739 ·Status: COMPLETED ·Phase: PHASE1
-
A Real-World Registry Investigating TReprostInil sodiUM in Pulmonary Hypertension (Re-TRIUMPH)
NCT05553015 ·Status: RECRUITING
-
Inhaled Treprostinil for PAH: Open-label Extension
NCT01557660 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
NCT02999906 ·Status: WITHDRAWN ·Phase: PHASE3
-
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
NCT03037580 ·Status: TERMINATED ·Phase: PHASE3
-
Impact of Hemo-dialysis Therapy on Blood Levels of Treprostenil in End Stage Renal Disease Patients With Pulmonary Hypertension
NCT01234571 ·Status: UNKNOWN
-
Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
NCT01557647 ·Status: WITHDRAWN ·Phase: PHASE3
-
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
NCT06350032 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
NCT05203510 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT00760916 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension
NCT00494533 ·Status: TERMINATED ·Phase: PHASE4
-
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
NCT03888365 ·Status: COMPLETED
-
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
NCT02276872 ·Status: COMPLETED ·Phase: PHASE2
-
Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study
NCT06605326 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
NCT01560637 ·Status: COMPLETED ·Phase: PHASE3
-
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
NCT06317805 ·Status: RECRUITING ·Phase: PHASE4